^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunosuppressant

    Related drugs:
    2d
    Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov)
    P3, N=110, Recruiting, AbbVie | Trial primary completion date: Jun 2027 --> Feb 2031
    Trial primary completion date
    5d
    ADIVKT: Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients (clinicaltrials.gov)
    P4, N=14, Active, not recruiting, University of California, Davis | Recruiting --> Active, not recruiting | N=50 --> 14 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    7d
    Anti-alpha-actinin Antibodies and Lupus Nephritis Activity (clinicaltrials.gov)
    P=N/A, N=96, Not yet recruiting, Assiut University
    New trial
    |
    cyclophosphamide
    8d
    Severe Myocarditis after Nivolumab and Ipilimumab in a Patient with Microsatellite Instability-High Gastric Adenocarcinoma: A Case Report. (PubMed, Niger J Clin Pract)
    The patient was managed with corticosteroids, mycophenolate mofetil (MMF), and intravenous immunoglobulin G (IVIG), but later developed supraventricular tachycardia and deep vein thrombosis. This report emphasizes the need to enhance recognition of immune-related toxicities within non-oncology specialties to support prompt interdisciplinary collaboration and appropriate patient management. Additionally, patients can develop myocarditis-related complications even when clinically stable or near the end of treatment, underscoring the need for close and ongoing monitoring.
    Journal • Microsatellite instability • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    9d
    A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia (clinicaltrials.gov)
    P=N/A, N=224, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    cyclophosphamide
    12d
    FREXERA: A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (clinicaltrials.gov)
    P2/3, N=526, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open
    |
    prednisone
    12d
    Anti-Psoriatic Effects of J2H-1802, a Mycophenolate Mofetil and 5-Aminosalicylic Acid Hybrid, in an Imiquimod-Induced Psoriasis-like Mouse Model. (PubMed, Pharmaceutics)
    In addition, J2H-1802 significantly reduced serum tumor necrosis factor-α (TNF-α) levels and suppressed pro-inflammatory cytokine expression, including IL-1β, IL-6, IL-17, and TNF-α, in psoriatic skin. J2H-1802 alleviates both local and systemic inflammatory features of psoriasis, suggesting its potential as a therapeutic candidate for targeting IL-23/Th17-mediated inflammatory pathways.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • IL1B (Interleukin 1, beta)
    |
    Zyclara (imiquimod)
    14d
    LUPUS-MONITOR: Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Federal University of Maranhao
    New trial
    16d
    Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility (clinicaltrials.gov)
    P=N/A, N=38, Active, not recruiting, Baylor Research Institute | N=20 --> 38 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    19d
    The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient (clinicaltrials.gov)
    P4, N=4, Terminated, CAMC Health System | N=40 --> 4
    Enrollment change
    19d
    Neuro-KTR: Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients (clinicaltrials.gov)
    P4, N=92, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    23d
    WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov)
    P1/2, N=120, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open